225 related articles for article (PubMed ID: 24601173)
1. The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis.
Musanovic A; Trnacevic S; Mekic M; Musanovic A
Med Arch; 2013; 67(5):361-4. PubMed ID: 24601173
[TBL] [Abstract][Full Text] [Related]
2. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
3. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
Takasawa K; Takaeda C; Wada T; Ueda N
Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
[No Abstract] [Full Text] [Related]
4. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
[TBL] [Abstract][Full Text] [Related]
5. A linear relationship between serum high-sensitive C-reactive protein and hemoglobin in hemodialysis patients.
Heidari B; Fazli MR; Misaeid MA; Heidari P; Hakimi N; Zeraati AA
Clin Exp Nephrol; 2015 Aug; 19(4):725-31. PubMed ID: 25380841
[TBL] [Abstract][Full Text] [Related]
6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
8. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
9. Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis.
Kuragano T; Yahiro M; Kida A; Furuta M; Nagasawa Y; Hasuike Y; Nanami M; Nakanishi T
Int J Artif Organs; 2014 Dec; 37(12):865-74. PubMed ID: 25450320
[TBL] [Abstract][Full Text] [Related]
10. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
11. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapy.
Biesenbach G; Schmekal B; Eichbauer-Sturm G; Janko O
Wien Klin Wochenschr; 2004 Dec; 116(24):844-8. PubMed ID: 15690969
[TBL] [Abstract][Full Text] [Related]
13. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Reticulocyte Hemoglobin Equivalent in Management of Regular Hemodialysis Patients with Iron Deficiency Anemia.
Dalimunthe NN; Lubis AR
Rom J Intern Med; 2016; 54(1):31-6. PubMed ID: 27141568
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
[TBL] [Abstract][Full Text] [Related]
16. Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.
Wan L; Zhang D
Int Urol Nephrol; 2018 Aug; 50(8):1511-1518. PubMed ID: 29946818
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
Richardson D; Lindley EJ; Bartlett C; Will EJ
Am J Kidney Dis; 2003 Sep; 42(3):551-60. PubMed ID: 12955684
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients.
Mitsopoulos E; Lysitska A; Pateinakis P; Lamprou V; Intzevidou E; Minasidis I; Katsaounou C; Kougioumtzidou O; Anagnostou N; Lemonidis N; Papadopoulou D
Int Urol Nephrol; 2020 Feb; 52(2):387-392. PubMed ID: 31894555
[TBL] [Abstract][Full Text] [Related]
19. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
20. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
